thumbnail
Deal Making2seventy deal to bulk out Regeneron’s cell therapy pipeline2seventy deal to bulk out Regeneron’s cell therapy pipeline
Regeneron has expanded its cell therapy business with the acquisition of 2seventy’s oncology and autoimmune R&D programs.